Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic’s Proposed Merger with Standard BioTools
BOULDER, Colo., Dec. 28, 2023 /PRNewswire/ — Dr. Larry Gold, the founder of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic’s current Chief Technology Officer, are issuing the below letter to SomaLogic’s stockholders regarding their opposition to the Company’s proposed merger with Standard BioTools, Inc. (“Standard”) (Nasdaq: LAB).
Related news for (SLGC)
- SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
- Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools
- Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools
- SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting “FOR” Pending Merger with Standard BioTools
- Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures